

Clinical Trial Protocol

Iranian Registry of Clinical Trials

25 Jul 2026

Evaluation of the effect of oral chicory extract on liver enzymes in patients with acute lymphoblastic leukemia: A clinical trial

Protocol summary

Study aim

Determining the effect of chicory extract on liver enzymes in patients with acute lymphoblastic leukemia

Design

This study is a double-blinded clinical trial with a parallel design and a control group. The study population will include all eligible children with acute lymphoblastic leukemia referred to Mohammad Kermanshahi Hospital. A total of 110 eligible people will be selected conveniently. A table of random numbers is used for randomization and the participants will assigned to two intervention and control groups

Settings and conduct

Mohammad Kermanshahi Hospital. The patient receives syrup extract daily, and by measuring liver tests, if they worsen, they are dropped from the study.

Participants/Inclusion and exclusion criteria

ALL children whose blood levels of liver enzymes are more than 2-4 times normal are included in the study, and in case of hepatitis and liver failure, they are excluded from the study.

Intervention groups

Intervention group: The patient should take some chicory plant extract as a supplement daily, and liver tests will be measured at the beginning of the study, 1.5 months, 3 months and 6 months later, and will be recorded in a special form in case of deterioration. The patient's liver conditions will be excluded from the study. The patient will be in this study for 6 months, and during this period, the patient's blood should be taken four times in Mohammad Kermanshahi Hospital to check the level of liver enzymes. Control group: Half of the patients are given a placebo (zinc sulfate syrup) daily. Finally, the result of the study will be for the treatment of cancer patients.

Main outcome variables

Serum bilirubin level, Level of liver enzymes AST, Level of ALT liver enzymes,

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220526055001N1**

Registration date: **2022-11-16, 1401/08/25**

Registration timing: **retrospective**

Last update: **2022-11-16, 1401/08/25**

Update count: **0**

Registration date

2022-11-16, 1401/08/25

Registrant information

Name

Sima Shareghi ghahreman

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 8889 7368

Email address

sara.kooti@kums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-09-14, 1401/06/23

Expected recruitment end date

2022-10-22, 1401/07/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of oral chicory extract on liver enzymes in patients with acute lymphoblastic leukemia: A clinical trial	
Public title	Efficacy of chicory plant syrup on liver enzymes in patients with acute lymphoblastic leukemia
Purpose	Treatment
Inclusion/Exclusion criteria	Inclusion criteria: Children with acute lymphoblastic leukemia (ALL) who have blood levels of liver enzymes more than 4-2 times normal are included in the study. In the consent form, giving the participants the right to choose to participate or not to participate in the research and to keep the information confidential. A written consent form from the child or their parents is the moral obligation of the researcher not to impose costs on the patients. Exclusion criteria: In case of hepatitis and liver failure, they will be excluded from the study.
Age	To 17 years old
Gender	Both
Phase	N/A
Groups that have been masked	• Outcome assessor
Sample size	Target sample size: 110
Randomization (investigator's opinion)	Randomized
Randomization description	Simple random method. 110 cards are selected and numbers from 1-110 are inserted on the cards. The cards are placed in an envelope. Two of the design partners take one card out of the envelope each time and announce the card number. If this number is 0, 1, 2, 3, 4, it will be assigned in the first intervention group, and if this number is 5, 6, 7, 8, 9, it will be assigned in the second intervention group.
Blinding (investigator's opinion)	Double blinded
Blinding description	The current study is a double blind clinical trial study. The observer and statistician do not know about the allocation of people to the intervention and control groups. To blind the observer, a person outside the research team performs the liver tests on the patients and does not know the type of medicine that the patients receive. For the purpose of blinding the statistician, the coded data is provided to him for analysis.
Placebo	Used
Assignment	Parallel
Other design features	

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Kermanshah University of Medical Sciences

Street address

Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences, Building No.2, Shahid Beheshti Boulevard

City

Kermanshah

Province

Kermanshah

Postal code

6715847141

Approval date

2022-04-24, 1401/02/04

Ethics committee reference number

IR.KUMS.MED.REC.1401.004

Health conditions studied

1

Description of health condition studied

Acute lymphoblastic leukemia

ICD-10 code

C91.0

ICD-10 code description

Acute lymphoblastic leukemia [ALL]

Primary outcomes

1

Description

Level of ALT liver enzymes

Timepoint

The beginning of the study, one and a half months, three and six months after the end of the study

Method of measurement

blood test

2

Description

Level of liver enzymes AST

Timepoint

The beginning of the study, one and a half months, three and six months after the end of the study

Method of measurement

blood test

3

Description

Serum bilirubin level

Timepoint

The beginning of the study, one and a half months, three and six months after the end of the study

Method of measurement

blood test

Secondary outcomes

empty

Intervention groups

1

Description

The intervention group will receive 5 cc chicory plant extract (Produced by Razi University Pharmaceutical Department) in the form of syrup as a daily supplement for one week to one and up to 3 months based on the level of liver enzymes.

Category

Treatment - Drugs

2

Description

The control group will receive zinc sulfate syrup as a placebo daily.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Dr. Mohammad Kermanshahi Superspeciality Hospital

Full name of responsible person

Dr. Mohammad Reza Golpaygani

Street address

Dr. Mohammad Kermanshahi Superspeciality Hospital

City

Kermanshah

Province

Kermanshah

Postal code

6714415333

Phone

+98 918 830 2455

Email

sara.kooti@kums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Dr. Cyrus Jalili

Street address

Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences, Building No.2, Shahid Beheshti Boulevard

City

Kermanshah

Province

Kermanshah

Postal code

6715847141

Phone

+98 83 3836 0014

Email

cjalili@kums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source

Kermanshah University of Medical Sciences

Proportion provided by this source

50

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Dr. Mohammad Reza Golpaygani

Position

Member of the academic staff of Kermanshah University of Medical Sciences

Latest degree

Subspecialist

Other areas of specialty/work

Hematology

Street address

Hellal ahmar crossroad, Hosseinieh Andisheh Park

City

Kermanshah

Province

Kermanshah

Postal code

6714415333

Phone

+98 918 830 2455

Email

Person responsible for scientific inquiries

Contact

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Dr. Mohammad Reza Golpaygani

Position

Member of the academic staff of Kermanshah
University of Medical Sciences

Latest degree

Subspecialist

Other areas of specialty/work

Hematology

Street address

Hellal ahmar crossroad, Hosseiniyeh Andisheh Park

City

Kermanshah

Province

Kermanshah

Postal code

6714415333

Phone

+98 918 830 2455

Email

sara.kooti@kums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Dr. Sima Shareghi Ghahraman

Position

Rezident

Latest degree

Specialist

Other areas of specialty/work

Pediatrics

Street address

Hellal ahmar crossroad, Hosseiniyeh Andisheh Park

City

Kermanshah

Province

Kermanshah

Postal code

6714415333

Phone

+98 912 377 3604

Email

simashareghi209@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available